Neumora Therapeutics (NMRA) Enterprise Value (2023 - 2026)

Neumora Therapeutics' Enterprise Value history runs 5 years deep, the most recent figure standing at -$147.1 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 41.02% year-over-year to -$147.1 million; the TTM figure through Mar 2026 stood at -$147.1 million (up 41.02% YoY), while the FY2025 annual figure was -$182.5 million, down 27.32% from the prior year.
• Enterprise Value for Q1 2026 stood at -$147.1 million, up from -$182.5 million in the prior quarter.
• The five-year high for Enterprise Value was -$124.5 million in Q2 2025, with the low at -$509.6 million in Q3 2023.
• The 5-year median for Enterprise Value is -$249.4 million (2025), against an average of -$274.3 million.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value plunged 101.8% in 2023, then surged 68.42% in 2024.
• Neumora Therapeutics' Enterprise Value stood at -$371.9 million in 2022, then slipped by 22.08% to -$454.0 million in 2023, then soared by 68.42% to -$143.4 million in 2024, then retreated by 27.32% to -$182.5 million in 2025, then grew by 19.43% to -$147.1 million in 2026.
• Business Quant data shows NMRA's Enterprise Value at -$147.1 million in Q1 2026, -$182.5 million in Q4 2025, and -$129.1 million in Q3 2025.